Other Type Line Grows 13.78% a Year and Takes Share From the Largest Cervical Disc Replacement Construct
Devices grouped under Other are the fastest-growing type line in the global cervical total disc replacement device market, expanding at 13.78% a year. Most of that gain comes at the expense of Metal On A Biocompatible Material (M-O-B) constructs. Other held 25% of revenue in 2025 and reaches 34% by 2034, with its value rising from USD 0.3375 billion to USD 1.1458 billion. Over the same years, M-O-B gives up ground, falling from 60% of revenue to 55%.
Market Size and the Pull Toward Motion Preservation
The market was valued at USD 1.35 billion in 2025. Contrive Datum Insights projects USD 1.57 billion in 2026 and USD 3.37 billion by 2034, a compound annual growth rate of 10.02% during the forecast period.
The study names rising adoption of motion-preserving surgery over spinal fusion as the largest single contributor to that growth, and it rates the impact high. These devices are artificial discs, implanted through the front of the neck, that replace a damaged or degenerated cervical disc while keeping movement at that level. Hospitals and ambulatory surgical centers buy them for spine and orthopedic surgeons, who pick the construct and level configuration patient by patient. As surgeons move toward preserving motion, the lines most exposed to that choice grow fastest.
The same pattern shows up on other axes. By material, Biocompatible grows fastest at 13.29%, and Polymeric led 2025 with 34% of revenue. By application, Clinics grows fastest at 12.84% while Hospitals led with 68%. By indication, Cervical Myelopathy grows at 12% and Degenerative Disc Disease led with 46%. By number of levels treated, Multi-Level grows at 13.29% against a 74% share for Single-Level.
The report brackets its base case with two scenarios. The bull case reaches USD 3.82 billion in 2034 if multi-level coverage expands faster than expected across major reimbursement markets and a further next-generation material construct wins approval early. The bear case holds revenue to USD 2.9 billion if multi-level reimbursement stalls in a major market and surgeons keep favoring fusion for longer than assumed.
Regions, and the Counterweight in the Largest Line
North America accounted for 46% of 2025 revenue, or USD 0.621 billion, and reaches USD 1.4154 billion by 2034. Asia Pacific is gaining ground, moving from 18% of revenue to 22% as its value grows from USD 0.243 billion to USD 0.7414 billion. Middle East and Africa stays the smallest region, at 4% in 2025 and 5% by 2034. The United States is the largest single country market, at USD 0.546 billion in 2025 and 40.48% of global revenue.
The largest type line sets the counterweight. M-O-B carried USD 0.81 billion in 2025 and is still the biggest line at the end of the forecast, yet it grows at 8.96%, below the 10.02% pace of the market as a whole. A line holding 60% of the base and growing slower than the total pulls the overall rate down, and it is the reason Other's climb matters so much to the headline figure.
The report covers five segmentation axes: type, material, application, indication and number of levels treated. It gives revenue and a growth rate for every line in every year from 2020 to 2034, covers all five regions with country-level breakdowns, and sets out the competitive landscape and the research methodology behind each estimate. It is delivered as a PDF, and a free sample is available on request.